ClinicalTrials.gg
CompletedNCT02623946Updated Jul 28, 2021

Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients

An observational study in Multiple Sclerosis, sponsored by Clinique Neuro-Outaouais. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-28.

Sponsored by Clinique Neuro-Outaouais · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.

Enrollment
41st of 42
10 · median 172
Started
2015
with 6 others
Observational
42 of 257
2 open now
Registered
140th of 257
by date
Lead sponsor
6 of 257
Clinique Neuro-Outaouais

Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 41st largest by enrollment of the 42 observational ones that give a count, is one of 7 that started in 2015, is one of 42 observational ones, and was the 140th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 257 studies in Multiple Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

Study Design:

Phase 4, pilot, single center, observational study. MEP's will be obtained twice, two weeks apart at baseline and every 6 months for 36 months (total of 14 sessions of MEP's)

MEP's will include:

  1. Onset latencies and CMCT to bilateral abductor pollicis brevis and tibialis anterior muscles
  2. MEP amplitudes and the ratio of the central to peripherally obtained motor amplitudes (MEP-M ratio) to bilateral abductor pollicis brevis and tibialis anterior muscles Clinical measures (EDSS, MEP's, T25FWT, 6MWT, 9HPT) will be obtained at baseline and every 6 months for 36 months.

Study location: Single center in Canada

Study Objectives:

Primary: To evaluate the reliability of MEP's in Alemtuzumab treated MS patients over a 36 month period.

Secondary: To determine the degree of correlation between MEP's and presently used clinical measures of efficacy (EDSS, 6MWT, T25FWT, 9HPT) and to determine if MEP's can predict who will require a third cycle of Alemtuzumab.

Read the detailed description

Alemtuzumab pivotal studies have shown robust effect on relapse rate and MRI parametric. The effect on disease progression did not however reach statistical significance in CARE MS I Clinical trials, especially in the progressive forms of Multiple Sclerosis (MS) have been greatly hampered by the insensitivity of the Expanded Disability Status Scale (EDSS) especially at either ends of the scale. Other more recently introduced clinical scales such the timed 25 foot walk test (T25FWT), six minute walk test (6MWT) or the 9-hole peg test (9HPT) also lack in sensitivity and reliability. A validated, sensitive and reliable biomarker for disability progression or regression would greatly help clinical research in MS. Such a biomarker could also help in evaluating if and when patients would require retreatments with Alemtuzumab.

Motor evoked potentials (MEP's) measures the integrity and function of corticospinal tracts. The procedure uses an electromagnet to induce directly or via interneurons a small depolarizing current in the axon hillock of large pyramidal neurons in the motor cortex. A subsequent motor response can then be measured in the targeted limb muscle. The amplitude and latency of such response can be measured giving an indication of the conduction integrity of the corticospinal tracts (CST) from the cortex to the limb. MEP's are able to detect perhaps even before clinical measures, evidence of CST involvement and deterioration through increased central motor conduction time and/or reduced ratio of centrally elicited MEP amplitude to peripherally elicited compound motor amplitude potential (CMAP).

MEP's have been studied in a variety of pathologies involving CST's. MEP's have in patients with cervical spondylosis as well as with patients with amyotrophic lateral sclerosis, shown to being more sensitive than clinical examination in detecting CST involvement. MEP's have been shown in MS to correlate with EDSS scores. In studies looking at spinal cord injury patients MEP's were able to demonstrate an improvement in central motor conduction time (CMCT) induced by extended release fampridine.

The main critique of MEP's has been as in all electrophysiological tests one of high intra-patient variability which can be compounded by non-standardized techniques between centers. Newer MEP techniques using neuro-navigation, standardized facilitation techniques and choosing the best of three responses can significantly reduce the inherent variability of obtained values. We believe that with such techniques MEP's can become a useful surrogate biomarker in clinical trials of MS. The latter however needs to be validated in a prospective manner.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • motor evoked potentials
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with MacDonald criteria (2005) multiple sclerosis presently being treated with Alemtuzumab.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MS (McDonald criteria) and of age 18 and older;
  • Subjects who meet the prescribing criteria for Alemtuzumab as per product monograph;
  • An EDSS of 5.0 or less and a pyramidal system functional assessment score of 2 or greater;
  • Subject who have received the first cycle of Alemtuzumab within the last 3 months.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have begun using extended release Fampridine within 2 months of study baseline visit (Patient on a stable dose of extended release Fampridine for more than 2 months can enter the study);
  • Subjects with MSSS (Multiple Sclerosis Severity Score) less than 4.0;
  • Subject with other medical conditions that involve the CST's;
  • Any other condition that would preclude them from undergoing the MEP's and/or MRI.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. intrapatient correlation coefficient of MEP's

    to measure within subject correlation a two-way fixed Intraclass Correlation (ICC) will be calculated for each of 10 participants across sessions measured two weeks apart. The ICC will provide an estimate of the variance of each individual's motor evoked potentials at each paired time point.

    Time frame: obtained between two assessments done two weeks apart

Secondary outcomes

  1. Correlation coefficient between the changes from baseline MEP results and clinical measures (EDSS, 6MW, T25FWT, 9HPT)

    to measure the relationship between MEP change scores and the change scores of the clinical measures, several correlations will be run across 6 months intervals over the 36 month period. The corrrelation between the individual changes in MEP results and the propensity to require a third cycle of alemtuzumab will also be calcutlated.

    Time frame: obtained every 6 months for 36 months

  2. Correlation between the change in the conduction index and the change in clincal measures

    to measure the correlation betwen the conduction index results and the clinical measures and the change in the conduction index over time and the change in the clinical measures over the 36month period.

    Time frame: obtained at baseline and every 6 months over 36 months

07

Study locations

1 site
  • Clinique Neuro-Outaouais
    Gatineau, Quebec J8Y 1W2, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2020, 61 months.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's 61 months is above that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2015
First posted
Dec 8, 2015
StartActual
Nov 2015
Primary completionActual
Dec 9, 2020
CompletionActual
Feb 2021
Last update
Jul 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02623946
Lead sponsor
Clinique Neuro-Outaouais
Collaborators
CogState Ltd.
Responsible party
Dr. Francois Jacques (neurologist, Clinique Neuro-Outaouais) — Principal investigator
First posted
Dec 8, 2015
Start date
Nov 2015
Primary completion
Dec 9, 2020
Completion
Feb 2021
Last update
Jul 28, 2021

Study contacts

Francois H Jacques, MD
principal investigator · Clinic Neuro-Outaouais; Director

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion